

Frank B Furnari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8095396/publications.pdf>

Version: 2024-02-01

103
papers

14,004
citations

24978

57
h-index

31759

101
g-index

112
all docs

112
docs citations

112
times ranked

19474
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>TERT</i> promoter C228T mutation in neural progenitors confers growth advantage following telomere shortening <i>in vivo</i> . <i>Neuro-Oncology</i> , 2022, 24, 2063-2075.	0.6	9
2	The impact of phosphorylated PTEN at threonine 366 on cortical connectivity and behaviour. <i>Brain</i> , 2022, 145, 3608-3621.	3.7	4
3	Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors. <i>Neuro-Oncology</i> , 2021, 23, 400-411.	0.6	11
4	PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastoma. <i>Neuro-Oncology</i> , 2021, 23, 1072-1086.	0.6	23
5	Mechanisms of stearyl CoA desaturase inhibitor sensitivity and acquired resistance in cancer. <i>Science Advances</i> , 2021, 7, .	4.7	38
6	PI3K β inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	33
7	HGG-12. HUMAN IPSC-DERIVED H3.3K27M NEUROSPHERES: A NOVEL MODEL FOR INVESTIGATING DIPG PATHOGENESIS AND DRUG RESPONSE. <i>Neuro-Oncology</i> , 2021, 23, i19-i20.	0.6	0
8	A Key Pathway to Cancer Resilience: The Role of Autophagy in Glioblastomas. <i>Frontiers in Oncology</i> , 2021, 11, 652133.	1.3	4
9	OTEH-9. scRNA sequencing of proneural GBM avatar model reveals acquisition of oncogenic transcriptional programming and infers a developmental path towards a genomically unstable state. <i>Neuro-Oncology Advances</i> , 2021, 3, ii12-ii12.	0.4	0
10	Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. <i>Cell Reports</i> , 2021, 37, 109957.	2.9	38
11	Radiation-induced extracellular vesicle (EV) release of miR-603 promotes IGF1-mediated stem cell state in glioblastomas. <i>EBioMedicine</i> , 2020, 55, 102736.	2.7	35
12	EGFRvIII uses intrinsic and extrinsic mechanisms to reduce glioma adhesion and increase migration. <i>Journal of Cell Science</i> , 2020, 133, .	1.2	8
13	SMARCB1 loss interacts with neuronal differentiation state to block maturation and impact cell stability. <i>Genes and Development</i> , 2020, 34, 1316-1329.	2.7	30
14	Genome Engineering Evolves Brain Tumor Modeling. <i>Neurologia Medico-Chirurgica</i> , 2020, 60, 329-336.	1.0	7
15	Integrin $\alpha 5 \beta 1$ Internalizes Zika Virus during Neural Stem Cells Infection and Provides a Promising Target for Antiviral Therapy. <i>Cell Reports</i> , 2020, 30, 969-983.e4.	2.9	63
16	Longitudinal assessment of tumor development using cancer avatars derived from genetically engineered pluripotent stem cells. <i>Nature Communications</i> , 2020, 11, 550.	5.8	45
17	Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling. <i>Cell Metabolism</i> , 2019, 30, 525-538.e8.	7.2	130
18	Intron 1-Mediated Regulation of <i>EGFR</i> Expression in EGFR-Dependent Malignancies Is Mediated by AP-1 and BET Proteins. <i>Molecular Cancer Research</i> , 2019, 17, 2208-2220.	1.5	10

#	ARTICLE	IF	CITATIONS
19	NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling. <i>Nature</i> , 2019, 569, 570-575.	13.7	153
20	Oncogenic mutations at the EGFR ectodomain structurally converge to remove a steric hindrance on a kinase-coupled cryptic epitope. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10009-10018.	3.3	46
21	Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. <i>Cancer Cell</i> , 2019, 35, 504-518.e7.	7.7	102
22	Circular ecDNA promotes accessible chromatin and high oncogene expression. <i>Nature</i> , 2019, 575, 699-703.	13.7	343
23	Blockade of a Laminin-411 Notch Axis with CRISPR/Cas9 or a Nanobioconjugate Inhibits Glioblastoma Growth through Tumor-Microenvironment Cross-talk. <i>Cancer Research</i> , 2019, 79, 1239-1251.	0.4	61
24	When less is more: Gaining power through gene rearrangement of amplified EGFR. <i>Oncotarget</i> , 2019, 10, 2116-2117.	0.8	1
25	Mapping of genomic EGFRvIII deletions in glioblastoma: insight into rearrangement mechanisms and biomarker development. <i>Neuro-Oncology</i> , 2018, 20, 1310-1320.	0.6	27
26	FHL2 interacts with EGFR to promote glioblastoma growth. <i>Oncogene</i> , 2018, 37, 1386-1398.	2.6	25
27	Fluorescence Molecular Tomography for In Vivo Imaging of Glioblastoma Xenografts. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	4
28	MDA-9/Syntenin regulates protective autophagy in anoikis-resistant glioma stem cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 5768-5773.	3.3	91
29	Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. <i>Cancer Cell</i> , 2018, 34, 163-177.e7.	7.7	145
30	Regulation of protective autophagy in anoikis-resistant glioma stem cells by SDCBP/MDA-9/Syntenin. <i>Autophagy</i> , 2018, 14, 1845-1846.	4.3	30
31	YAP and MRTF-A, transcriptional co-activators of RhoA-mediated gene expression, are critical for glioblastoma tumorigenicity. <i>Oncogene</i> , 2018, 37, 5492-5507.	2.6	49
32	Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. <i>Nature</i> , 2017, 543, 122-125.	13.7	530
33	PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. <i>Nature Communications</i> , 2017, 8, 15223.	5.8	94
34	Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 370-375.	3.3	79
35	Glioblastoma cellular cross-talk converges on NF- κ B to attenuate EGFR inhibitor sensitivity. <i>Genes and Development</i> , 2017, 31, 1212-1227.	2.7	53
36	An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. <i>Cancer Cell</i> , 2016, 30, 683-693.	7.7	237

#	ARTICLE	IF	CITATIONS
37	Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. <i>Journal of Controlled Release</i> , 2016, 244, 14-23.	4.8	40
38	Epidermal growth factor receptor targeting and challenges in glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 914-918.	0.6	117
39	The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc ⁻ . <i>Cancer Research</i> , 2016, 76, 2954-2963.	0.4	84
40	Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition. <i>Oncotarget</i> , 2015, 6, 11751-11767.	0.8	9
41	ATPS-86 MUTATIONS IN THE EGF RECEPTOR EXTRACELLULAR DOMAIN REVEAL AN UNTETHERED TRANSITIONAL STATE WHICH MEDIATES mAb806 BINDING. <i>Neuro-Oncology</i> , 2015, 17, v37.3-v37.	0.6	0
42	CBIO-04DAXX INHIBITION SUPPRESSES TUMOR GROWTH IN PTEN-DEFICIENT HUMAN GLIOBLASTOMAS. <i>Neuro-Oncology</i> , 2015, 17, v55.4-v55.	0.6	0
43	Cancer-Associated Protein Kinase C Mutations Reveal Kinase's Role as Tumor Suppressor. <i>Cell</i> , 2015, 160, 489-502.	13.5	285
44	A Urokinase Receptor's Bim Signaling Axis Emerges during EGFR Inhibitor Resistance in Mutant EGFR Glioblastoma. <i>Cancer Research</i> , 2015, 75, 394-404.	0.4	48
45	Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. <i>Nature Reviews Cancer</i> , 2015, 15, 302-310.	12.8	305
46	EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. <i>Molecular Cell</i> , 2015, 60, 307-318.	4.5	161
47	A Unified Nomenclature and Amino Acid Numbering for Human PTEN. <i>Science Signaling</i> , 2014, 7, pe15.	1.6	50
48	Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA. <i>Science</i> , 2014, 343, 72-76.	6.0	460
49	Suppression of MicroRNA-9 by Mutant EGFR Signaling Upregulates FOXP1 to Enhance Glioblastoma Tumorigenicity. <i>Cancer Research</i> , 2014, 74, 1429-1439.	0.4	59
50	EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. <i>Journal of Clinical Investigation</i> , 2014, 124, 3741-3756.	3.9	82
51	Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. <i>Oncotarget</i> , 2014, 5, 882-893.	0.8	127
52	Nuclear EGFRvIII's STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-2 promoter. <i>International Journal of Cancer</i> , 2013, 132, 509-520.	2.3	41
53	The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas. <i>Clinical Cancer Research</i> , 2013, 19, 5722-5732.	3.2	46
54	A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. <i>Carcinogenesis</i> , 2013, 34, 725-738.	1.3	86

#	ARTICLE	IF	CITATIONS
55	A Kinome-Wide RNAi Screen in Drosophila Glia Reveals That the RIO Kinases Mediate Cell Proliferation and Survival through TORC2-Akt Signaling in Glioblastoma. PLoS Genetics, 2013, 9, e1003253.	1.5	114
56	PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4339-4344.	3.3	60
57	Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks. Cancer Biology and Medicine, 2013, 10, 192-205.	1.4	45
58	Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14164-14169.	3.3	97
59	Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3018-3023.	3.3	88
60	Emerging insights into the molecular and cellular basis of glioblastoma. Genes and Development, 2012, 26, 756-784.	2.7	463
61	Analysis of Phosphotyrosine Signaling in Glioblastoma Identifies STAT5 as a Novel Downstream Target of \hat{I}^{β} EGFR. Journal of Proteome Research, 2011, 10, 1343-1352.	1.8	44
62	Heterogeneity Maintenance in Glioblastoma: A Social Network. Cancer Research, 2011, 71, 4055-4060.	0.4	386
63	MicroRNA-138 Modulates DNA Damage Response by Repressing Histone H2AX Expression. Molecular Cancer Research, 2011, 9, 1100-1111.	1.5	146
64	Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. Journal of Experimental Medicine, 2011, 208, 2657-2673.	4.2	65
65	Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 15984-15989.	3.3	54
66	Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism. Journal of Cell Science, 2011, 124, 2938-2950.	1.2	35
67	Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. Journal of Clinical Investigation, 2011, 121, 161-173.	3.9	141
68	Activation of Rac1 by Src-dependent phosphorylation of Dock180Y1811 mediates PDGFR \hat{I}^{\pm} -stimulated glioma tumorigenesis in mice and humans. Journal of Clinical Investigation, 2011, 121, 4670-4684.	3.9	105
69	Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chinese Journal of Cancer, 2011, 30, 5-12.	4.9	116
70	Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. Journal of Cell Biology, 2011, 195, i10-i10.	2.3	0
71	Decoy for microRNAs. Nature, 2010, 465, 1016-1017.	13.7	44
72	Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma Therapy. PLoS ONE, 2010, 5, e10767.	1.1	59

#	ARTICLE	IF	CITATIONS
73	Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. <i>Genes and Development</i> , 2010, 24, 1731-1745.	2.7	454
74	Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 2616-2621.	3.3	63
75	Escape from targeted inhibition: The dark side of kinase inhibitor therapy. <i>Cell Cycle</i> , 2010, 9, 1661-1662.	1.3	12
76	Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth. <i>Molecular BioSystems</i> , 2010, 6, 1227.	2.9	40
77	Fyn and Src Are Effectors of Oncogenic Epidermal Growth Factor Receptor Signaling in Glioblastoma Patients. <i>Cancer Research</i> , 2009, 69, 6889-6898.	0.4	136
78	EGFRvIII and DNA Double-Strand Break Repair: A Molecular Mechanism for Radioresistance in Glioblastoma. <i>Cancer Research</i> , 2009, 69, 4252-4259.	0.4	232
79	A Drosophila Model for EGFR-Ras and PI3K-Dependent Human Glioma. <i>PLoS Genetics</i> , 2009, 5, e1000374.	1.5	179
80	The PTEN/PI3 Kinase Pathway in Human Glioma. , 2009, , 315-357.		3
81	Feedback Circuit among INK4 Tumor Suppressors Constrains Human Glioblastoma Development. <i>Cancer Cell</i> , 2008, 13, 355-364.	7.7	109
82	Uncovering Therapeutic Targets FOR Glioblastoma: A Systems Biology Approach. <i>Cell Cycle</i> , 2007, 6, 2750-2754.	1.3	63
83	The Efficacy of Epidermal Growth Factor Receptor-Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization. <i>Clinical Cancer Research</i> , 2007, 13, 1911-1925.	3.2	64
84	Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 12867-12872.	3.3	365
85	Malignant astrocytic glioma: genetics, biology, and paths to treatment. <i>Genes and Development</i> , 2007, 21, 2683-2710.	2.7	1,952
86	Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting. <i>Clinical Cancer Research</i> , 2006, 12, 5064-5073.	3.2	440
87	The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. <i>Cancer Cell</i> , 2006, 9, 379-390.	7.7	65
88	PCAF Modulates PTEN Activity. <i>Journal of Biological Chemistry</i> , 2006, 281, 26562-26568.	1.6	183
89	Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 2703-2706.	3.3	109
90	Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor-Specific Antibody Generates Enhanced Antitumor Activity. <i>Clinical Cancer Research</i> , 2005, 11, 6390-6399.	3.2	103

#	ARTICLE	IF	CITATIONS
91	PTEN: A Novel Anti-oncogenic Function Independent of Phosphatase Activity. <i>Cell Cycle</i> , 2005, 4, 540-542.	1.3	26
92	PHLPP: A Phosphatase that Directly Dephosphorylates Akt, Promotes Apoptosis, and Suppresses Tumor Growth. <i>Molecular Cell</i> , 2005, 18, 13-24.	4.5	796
93	Alix/AIP1 Antagonizes Epidermal Growth Factor Receptor Downregulation by the Cbl-SETA/CIN85 Complex. <i>Molecular and Cellular Biology</i> , 2004, 24, 8981-8993.	1.1	108
94	Immunohistochemical analysis of the mutant epidermal growth factor, $\hat{1}$ EGFR, in glioblastoma. <i>Brain Tumor Pathology</i> , 2004, 21, 53-56.	1.1	112
95	Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 6505-6510.	3.3	141
96	Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. <i>Cancer Research</i> , 2002, 62, 6764-9.	0.4	152
97	Malignant glioma: genetics and biology of a grave matter. <i>Genes and Development</i> , 2001, 15, 1311-1333.	2.7	1,064
98	The Protein Tyrosine Phosphatase TCPTP Suppresses the Tumorigenicity of Glioblastoma Cells Expressing a Mutant Epidermal Growth Factor Receptor. <i>Journal of Biological Chemistry</i> , 2001, 276, 46313-46318.	1.6	66
99	IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation. <i>Oncogene</i> , 2000, 19, 2687-2694.	2.6	75
100	SETA: A novel SH3 domain-containing adapter molecule associated with malignancy in astrocytes. <i>Neuro-Oncology</i> , 2000, 2, 6-15.	0.6	38
101	PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. <i>Oncogene</i> , 1999, 18, 3936-3943.	2.6	102
102	In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 9418-9423.	3.3	90
103	Molecular Biology of Malignant Degeneration of Astrocytoma. <i>Pediatric Neurosurgery</i> , 1996, 24, 41-49.	0.4	16